This segment focuses on the research, development, and clinical evaluation of oncolytic immunotherapies. Replimune utilizes its proprietary Immulytic platform to engineer oncolytic viruses, such as RP1, RP2, and RP3, designed to selectively replicate within cancer cells, leading to tumor cell lysis and the activation of the patient's immune system. Research and development activities include preclinical studies, clinical trial design and execution, and manufacturing process development. The therapeutic areas covered include a range of solid tumors, cutaneous squamous cell carcinoma, and colorectal cancer. The patient impact is aimed at improving survival rates and quality of life for cancer patients. Replimune's market positioning is as a clinical-stage biotechnology company with a focus on innovative cancer treatments. Competitive advantages include the Immulytic platform and strategic collaborations with Roche and Incyte. Future opportunities involve expanding the clinical trial portfolio and seeking regulatory approvals. Regulatory and clinical aspects include navigating FDA guidelines and conducting clinical trials to demonstrate safety and efficacy. Partnerships with Roche and Incyte support clinical development and commercialization efforts.